Regeneron Ventures

Regeneron Ventures is a healthcare-focused corporate venture capital fund launched in April 2024 with a $500 million commitment from its sole and exclusive limited partner, Regeneron Pharmaceuticals. The fund operates independently of Regeneron's internal R&D priorities, with its own investment committee and decision-making authority. Its mandate covers healthcare broadly, with a particular skew toward biotechnology, devices, tools, and enabling technologies. The fund is explicitly stage-agnostic; observed portfolio activity is concentrated at Series A and Series B, with occasional Series C investments. Investment decisions are based on the quality of people, science, and data. The fund is managed by former Regeneron executives Jay Markowitz and Michael Aberman, and is headquartered in Greenwich, Connecticut. Regeneron Pharmaceuticals commits $100 million annually over five years to the fund. No fixed check-size range is published.